# Effect of JAK Inhibitor on Erosion Healing in RA

> **NCT05955066** · PHASE4 · RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 60 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Baricitinib 4 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05955066
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2026-02
- **Final completion:** 2026-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05955066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05955066, "Effect of JAK Inhibitor on Erosion Healing in RA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05955066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*